Allergy vaccine - United Biomedical

Drug Profile

Allergy vaccine - United Biomedical

Alternative Names: Anti-IgE allergy vaccine - United Biomedical

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United Biomedical
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypersensitivity
  • No development reported Asthma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA
  • 23 Sep 2016 United Biomedical receives SBIR grant from the National Institute of Allergy and Infectious Diseases, for Allergy vaccine development in Hypersensitivity, before September 2016 (United Biomedical pipeline, September 2016)
  • 23 Sep 2016 Phase-I clinical trials in Hypersensitivity in USA (unspecified route), before September 2016 (United Biomedical pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top